What To Expect From Cellectis SA Q3 2024 Earnings
| CLLS Stock | USD 2.13 0.01 0.47% |
Slightly above 62% of Cellectis' investor base is looking to short. The analysis of overall sentiment of trading Cellectis SA stock suggests that many investors are alarmed at this time. Cellectis' investing sentiment can be driven by a variety of factors including economic data, Cellectis' earnings reports, geopolitical events, and overall market trends.
Cellectis |
Cellectis SA is set to release its Q3 2024 earnings on Nov 5, 2024. The consensus estimate for Q3 2024 revenue is 5.40 million, and the earnings are exp
Read at gurufocus.com
 |
Cellectis Fundamental Analysis
We analyze Cellectis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cellectis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cellectis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
Cellectis is currently under evaluation in target price category among its peers.
Cellectis SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cellectis stock to make a market-neutral strategy. Peer analysis of Cellectis could also be used in its relative valuation, which is a method of valuing Cellectis by comparing valuation metrics with similar companies.
Peers
Cellectis Related Equities
| GLUE | Monte Rosa | 5.93 | ||||
| RGNX | Regenxbio | 4.82 | ||||
| FHTX | Foghorn Therapeutics | 3.59 | ||||
| IPHA | Innate Pharma | 3.45 | ||||
| DMAC | DiaMedica Therapeutics | 2.56 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
| KYMR | Kymera Therapeutics | 1.91 | ||||
| CRNX | Crinetics Pharmaceuticals | 1.59 | ||||
| INBX | Inhibrx | 1.17 | ||||
| GNFT | Genfit | 0.95 | ||||
| STTK | Shattuck Labs | 0.93 | ||||
| KZR | Kezar Life | 0.40 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| NRIX | Nurix Therapeutics | 2.57 | ||||
| SLNO | Soleno Therapeutics | 4.29 | ||||
| PASG | Passage Bio | 10.67 | ||||
| HCWB | HCW Biologics | 10.71 |
Additional Tools for Cellectis Stock Analysis
When running Cellectis' price analysis, check to measure Cellectis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cellectis is operating at the current time. Most of Cellectis' value examination focuses on studying past and present price action to predict the probability of Cellectis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cellectis' price. Additionally, you may evaluate how the addition of Cellectis to your portfolios can decrease your overall portfolio volatility.